Form 4 for KAPA Kairos Pharma, LTD.
Accepted 2025-11-26 00:00:00 ET · period of report 2025-10-08 · accession 0001493152-25-025197 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-26 | 2025-10-08 | KAPA | Yu John S | CEO, COB, Dir, 10% | A - Grant | $0.00 | +190.8K | 230.1K | +486% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK | 2025-10-08 | A | A | 190,840 | $0.00 | 230,105 | D | — | — | (F1) Represents 190,840 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date. (F2) Consists of (1) 34,599 shares of common stock (2) 195,506 RSUs which remain subject to vesting. |